🇺🇸 MRK — Merck & Co., Inc.
Healthcare CompraPrecio actual
148,46 USD
Máx. histórico
156,92
14 días
Split 1048:1000 del 03/06/2021
Caída desde máximo
-5,39%
Rango 52 semanas
77,58 – 156,92
Variación hoy
-1,24%
Cierre anterior
150,33
Rango de hoy
146,28 – 149,59
Volumen hoy
10.884.998
- Nombre completo
- Merck & Co., Inc.
- Divisa
- USD
- Mercado
- NYSE
- Sector
- Healthcare
- Industria
- Drug Manufacturers - General
- Empleados
- 73.000
- PER ⓘ
- 118,77 (puede no estar actualizado)
- Dividend yield
- 2,26% (puede no estar actualizado)
- Precio objetivo analistas
- 150,42 USD (puede no estar actualizado)
- Primera cotización
- 02/01/1962
- Precio actualizado
- hace 1 hora
Merck & Co., Inc. operates as a healthcare company worldwide. It offers human health pharmaceutical for various areas under the Keytruda, Keytruda Qlex, Welireg, Gardasil, ProQuad, M-M-R II, Varivax, Vaxneuvance, Capvaxive, RotaTeq, Pneumovax 23, Bridion, Prevymis, Dificid, Zerbaxa, Winrevair, Adempas/ Verquvo, Ohtuvayre, Lagevrio, Isentress/Isentress HD, Delstrigo, Pifeltro, Belsomra, Januvia, and Janumet brands. The company also provides veterinary pharmaceuticals, vaccines and health management solutions and services, such as livestock products under the Nuflor, Bovilis/Vista, Bovilis Cryptium, Banamine, Estrumate, Matrix, Resflor, Zuprevo, Revalor, Safe-Guard, M+Pac, Porcilis, Circumvent, Nobilis/Innovax, Paracox and Coccivac, Exzolt, Slice, Imvixa, Clynav, Aquavac/Norvax, Aquaflor, Flexolt brands; Allflex Livestock Intelligence solutions; and companion animal products under the Bravecto One-Month, Bravecto Injectable/Quantum, Bravecto TriUNO, Bravecto Plus, Sentinel Spectrum, Sentinel Flavor Tabs, Numelvi, Optimmune, Nobivac NXT, GilvetMab, Otomax, Mometamax, Mometamax Ultra, Posatex, Caninsulin/Vetsulin, Panacur, Safeguard, Regumate, Prestige, Scalibor/Exspot, Sure Petcare, and Home Again brands. It has development and commercialization agreement for three of Daiichi Sankyo's deruxtecan ADC candidates; AstraZeneca PLC to co-development and co-commercialize AstraZeneca's Lynparza products for multiple cancer types; licensed to develop, manufacture and commercialize LM-299, a novel investigational PD-1/VEGF bispecific antibody from LaNova; and collaboration agreement with Eisai Co., Ltd., Bayer AG, and Ridgeback Biotherapeutics LP, as well Moderna, Inc. Merck & Co., Inc. has strategic collaboration with Infinimmune, Inc. to discover and develop antibodies against multiple therapeutic targets. The company was founded in 1891 and is headquartered in Rahway, New Jersey.
| Fecha de pago | Importe por participación |
|---|---|
| 14/12/2018 | 0,5248 USD |
| 14/09/2018 | 0,4580 USD |
| 14/06/2018 | 0,4580 USD |
| 14/03/2018 | 0,4580 USD |
| 14/12/2017 | 0,4580 USD |
| 14/09/2017 | 0,4485 USD |
| 13/06/2017 | 0,4485 USD |
| 13/03/2017 | 0,4485 USD |
| 13/12/2016 | 0,4485 USD |
| 13/09/2016 | 0,4389 USD |
| 13/06/2016 | 0,4389 USD |
| 11/03/2016 | 0,4389 USD |
| 11/12/2015 | 0,4389 USD |
| 11/09/2015 | 0,4294 USD |
| 11/06/2015 | 0,4294 USD |
| Fecha | Ratio |
|---|---|
| 03/06/2021 | 1048:1000 |
| 17/02/1999 | 2:1 |
| 26/05/1992 | 3:1 |
| 26/05/1988 | 3:1 |
| 27/05/1986 | 2:1 |
| 01/06/1972 | 2:1 |
| Fecha | Apertura | Máximo | Mínimo | Cierre | Variación | Volatilidad día | Volumen |
|---|---|---|---|---|---|---|---|
| 28/01/2003 | 50,55 | 52,57 | 50,36 | 51,91 | +5,10% | 4,36% | 10.412.614 |
| 27/01/2003 | 50,86 | 51,14 | 49,14 | 49,39 | -3,34% | 3,92% | 8.840.404 |
| 24/01/2003 | 52,81 | 52,91 | 50,95 | 51,10 | -3,25% | 3,70% | 7.394.478 |
| 23/01/2003 | 53,08 | 53,52 | 52,34 | 52,81 | -0,49% | 2,23% | 6.183.410 |
| 22/01/2003 | 54,13 | 54,20 | 53,05 | 53,07 | -1,94% | 2,12% | 7.951.281 |
| 21/01/2003 | 55,11 | 55,19 | 53,96 | 54,12 | -2,78% | 2,23% | 8.075.888 |
| 17/01/2003 | 55,58 | 56,22 | 55,07 | 55,67 | -0,87% | 2,08% | 6.209.714 |
| 16/01/2003 | 56,57 | 57,00 | 55,82 | 56,15 | -0,74% | 2,09% | 5.537.527 |
| 15/01/2003 | 57,07 | 57,19 | 56,36 | 56,57 | -0,87% | 1,45% | 4.014.050 |
| 14/01/2003 | 56,82 | 57,16 | 56,43 | 57,07 | +0,02% | 1,28% | 3.959.134 |
| 13/01/2003 | 57,25 | 57,48 | 56,66 | 57,06 | -0,02% | 1,43% | 4.456.934 |
| 10/01/2003 | 57,04 | 57,23 | 56,40 | 57,07 | +0,05% | 1,46% | 5.104.179 |
| 09/01/2003 | 56,30 | 57,25 | 55,81 | 57,04 | +1,36% | 2,56% | 7.411.037 |
| 08/01/2003 | 56,40 | 56,82 | 56,11 | 56,28 | -0,22% | 1,27% | 4.983.030 |
| 07/01/2003 | 56,87 | 57,30 | 56,34 | 56,40 | -1,29% | 1,69% | 6.692.947 |
| 06/01/2003 | 56,06 | 57,22 | 56,06 | 57,14 | +1,51% | 2,08% | 4.852.659 |
| 03/01/2003 | 55,82 | 56,53 | 55,73 | 56,29 | +1,27% | 1,42% | 5.419.837 |
| 02/01/2003 | 54,94 | 55,82 | 54,68 | 55,58 | +2,90% | 2,08% | 6.104.076 |
| 31/12/2002 | 53,63 | 54,17 | 53,44 | 54,02 | -0,35% | 1,37% | 4.192.629 |
| 30/12/2002 | 53,43 | 54,65 | 53,33 | 54,21 | +1,45% | 2,46% | 5.157.208 |
| 27/12/2002 | 54,39 | 54,53 | 53,17 | 53,44 | -1,65% | 2,51% | 3.272.275 |
| 26/12/2002 | 54,60 | 55,46 | 54,25 | 54,33 | +0,02% | 2,22% | 3.710.444 |
| 24/12/2002 | 54,25 | 54,69 | 54,18 | 54,32 | +0,49% | 0,95% | 2.357.476 |
| 23/12/2002 | 53,96 | 54,71 | 53,72 | 54,06 | +0,51% | 1,84% | 6.715.584 |
| 20/12/2002 | 53,93 | 54,39 | 53,58 | 53,78 | +0,14% | 1,50% | 9.298.799 |
| 19/12/2002 | 53,96 | 54,65 | 53,40 | 53,70 | -1,02% | 2,32% | 5.437.129 |
| 18/12/2002 | 55,34 | 55,41 | 54,03 | 54,26 | -2,47% | 2,50% | 5.628.494 |
| 17/12/2002 | 55,83 | 56,07 | 55,44 | 55,63 | -0,34% | 1,13% | 4.961.756 |
| 16/12/2002 | 55,20 | 55,87 | 54,87 | 55,82 | +2,02% | 1,82% | 5.494.035 |
| 13/12/2002 | 53,84 | 55,43 | 53,84 | 54,71 | +0,31% | 2,96% | 5.681.522 |